Evidence map›Paper›PMID 39134710›Full record

ArticleBone marrow transplantation2024

Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients.

Krithika Shanmugasundaram, Scott Napier, Dimana Dimitrova, Anita Stokes, Jennifer Wilder, Amy Chai, Andrea Lisco, Megan V Anderson, Irini Sereti, Gulbu Uzel and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Krithika ShanmugasundaramCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1006-4609
Scott Napier *Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Dimana Dimitrova *Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4868-6852
Anita StokesCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer WilderClinical Center, National Institutes of Health, Bethesda, MD, USA.
Amy ChaiCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Andrea LiscoHIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Megan V AndersonHIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Irini SeretiHIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0076-0224
Gulbu UzelLaboratory of Clinical Immunology and Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alexandra F FreemanLaboratory of Clinical Immunology and Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Christi McKeownCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer SponaugleCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ruby SabinaCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kamil RechacheCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mustafa A HyderCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer A KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jennifer.kanakry@nih.gov.
Christopher G KanakryCenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. christopher.kanakry@nih.gov.ORCID http://orcid.org/0000-0002-7736-2056

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic efficacy of donor lymphocyte infusions (DLIs) given after allogeneic hematopoietic cell transplantation (HCT) is limited by risk of graft-versus-host disease (GVHD). Post-transplantation cyclophosphamide (PTCy) effectively prevents severe GVHD, but there are limited data on outcomes of DLIs given to PTCy-treated patients. We reviewed 162 consecutive PTCy-treated patients transplanted between 2015-2022 within the Center for Immuno-Oncology at the National Cancer Institute. Of 38 DLIs given to 21 patients after 22 HCTs, few DLIs were associated with toxicities of acute GVHD (7.8%), cytokine release syndrome (CRS, 7.8%), or chronic GVHD (2.6%), and all occurred in those receiving serotherapy-containing pre-HCT conditioning (50% of HCTs). Seven DLIs resulted in complete response (18.4%), with 5 of these given after HCTs using serotherapy-containing conditioning. Excluding infectious indications, complete response to DLIs given after transplants with versus without serotherapy-containing pre-HCT conditioning were 30% and 4.3%, respectively. Two patients received DLI for infection and experienced complete resolution without GVHD or CRS, although the efficacy cannot be definitively attributable to the DLI. DLIs given to PTCy-treated patients had low toxicity but limited efficacy, although pre-HCT serotherapy may modulate both toxicity and response. Novel strategies are needed to enhance the therapeutic efficacy of post-transplant cellular therapies without aggravating GVHD.

Indexed as

CyclophosphamideGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLymphocyte TransfusionAdolescentAdultAgedAllograftsFemaleHumansMaleMiddle AgedTissue DonorsTransplantation ConditioningYoung AdultCyclophosphamide

Identifiers

PMID39134710
PMCPMC11530367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.